ABOUT
Since 2003, Pluri has perfected methods to consistently expand a single placenta cell into billions of distinct cells.
The cell expansion process drives the development of groundbreaking cell-based therapies targeting a variety of medical indications. These therapies are ushering in a new era of more targeted, personalized, and well-tolerated treatments.
Because Pluri’s placenta-derived, allogeneic product candidates do not require genetic or tissue matching prior to administration, they can potentially be delivered in almost any clinical setting.
Our preclinical and clinical programs explore a wide range of therapeutic areas,
including vascular disease, inflammation-related conditions, muscle injuries and hematological disorders.
Our growing pipeline of differentiated products includes potential candidates to meet some of medicine’s most challenging unmet needs around the world.
These are being developed in our in-house, Good Manufacturing Practices
manufacturing facility.
Pluri is proud to hold over 250 patents.
Our Chemistry, Manufacturing, and Control (CMC) was approved for use in clinical studies by key regulators, such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Israeli Ministry of Health (MOH), Japan’s Pharmaceuticals and Medical Devices Agency
(PMDA) and Korean MFDA.
Pluri has collaborated and received support from the U.S. National Institutes of Health (NIH), Department of Defense (DoD), National Aeronautics and Space Administration (NASA) and the Israel Innovation Authority (IIA).
Pluri received financial support from the European Investment Bank in the form of €50 million non-dilutive financing. Over the years Pluri has been awarded approximately €30 Million non-dilutive funding from the European Union’s research and development programs (Horizon 2020 and Horizon Europe). Each grant has been awarded to the relevant collaborative project, carried out by aninternational consortium, to support clinical and research activities for Pluri’s cell therapy.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.